3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
8
Phase 2
2
Phase EARLY_PHASE1
1
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
73
Plasma cell
60
Other hematologic neoplasm
27
Genitourinary
6
Gynecologic
4
Gastrointestinal
4
Myeloid
3
Thoracic
2
Head & Neck
2
Tumor-Agnostic
1
Sarcoma
1
Endocrine
1
Dermatologic
1
Classical hematology
1
CNS
1
Conditions
Neurologic Manifestations
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Central Nervous System Neoplasms
1
Interventions
Temozolomide
102
Radiotherapy
47
Bevacizumab
33
Carboplatin
23
Irinotecan
20
pembrolizumab
17
Radiosurgery
16
Nivolumab
16
Radiation
14
Cyclophosphamide
11
Magnetic Resonance Spectroscopy
10
fludarabine
8
Trastuzumab
8
Radiotherapy, Intensity-Modulated
8
Carmustine
8
Surgical Procedures, Operative
7
Specimen Handling
7
Pemetrexed
7
Paclitaxel
7
Interleukin-2
7
Filgrastim
7
Everolimus
7
Erlotinib Hydrochloride
7
temsirolimus
6
Vorinostat
6
Radiotherapy, Conformal
6
Lomustine
6
Ipilimumab
6
Granulocyte-Macrophage Colony-Stimulating Factor
6
Gemcitabine
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lenalidomide
×
CNS
×
Clear all
NCT04446962
2025-09-25
LOC-R01
Institut Curie
Phase 1/2
Active not recruiting
118 enrolled